Fold expansion of identified neoantigen-specific T cell responses in peripheral blood
| Gene mutation | Peak of neoantigen-specific T cell frequency in blood (months after TIL infusion) | Minimal fold expansion compared with preinfusion at peak | |
| Patient 3 | RBM12 S>L | 6 | 750 |
| VARS T>M | 9 | 8* | |
| MYLK G>V | 3 | 92* | |
| LRP3 T>S | Not detected in blood | Not applicable | |
| WDR1 N>K | 3 | 30* | |
| Patient 4 | TTC37 A>V | No expansion observed | 1 |
| ENTPD4 P>L | 3 | 17 | |
| MAB21L1 V>M | Not detected in blood | Not applicable | |
| Patient 8 | RAD51AP1-002 S>F | 4 | 25 |
*Calculated using the detection limit of the assay for the preinfusion time point, which is 0.002% MHC multimer+ of total CD8+ T cells.
MHC, major histocompatibility complex; TIL, tumor infiltrating lymphocyte.